FDA Grants Orphan Drug Status to Naproxcinod for Pain Crises

Naproxcinod, an investigational therapy being developed by Fera Pharmaceuticals as a treatment for sickle cell disease (SCD), has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA). Orphan drug status provides regulatory support and financial benefits to experimental treatments for diseases that affect fewer…

Fera Requests FDA Orphan Drug Designation for Naproxcinod for SCD

Fera Pharmaceuticals submitted an application to the U.S. Food and Drug Administration (FDA) requesting orphan drug status for naproxcinod, a potential treatment for for sickle cell disease (SCD). Orphan drug designation is given to experimental treatments for rare diseases (those that affect…